Skip to main content
Premium Trial:

Request an Annual Quote

DeCode s Shares Rebound After Mid-day Dip Following Positive Drug Data

This article has been updated from a previous version. Share prices have been updated.


NEW YORK, Oct. 19 (GenomeWeb News) - Shares in DeCode Genetics closed up more than11 percent at $7.36 yesterday, regaining lost ground after the stock dipped mid-day following after the Icelandic pharmacogenomics company announced positive results from an ongoing drug trial.


Shares in the Icelandic pharmacogenomics company were at $7.31 in early-morning trading on the Nasdaq exchange today. They reached a high of $7.70 yesterday, but  receded to $6.90 in afternoon trade.


DeCode licensed the drug, which is in early-stage Phase IIa clinical testing, from  Bayer last November

Results of the study showed the drug, called DG031, to have significantly reduced levels of two chemical biomarkers associated with arterial inflammation and myocardial infarction risk.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.